Claims
- 1. A method for inducing an immunological response in a host comprising the steps of:
administering to the host at least one antigen; and administering to the host a lipoprotein.
- 2. The method of claim 1 wherein the antigen and the lipoprotein are administered simultaneously.
- 3. The method of claim 1 wherein the antigen exhibits epitopes of a bacterial protein.
- 4. The method of claim 3 wherein the antigen is urease.
- 5. The method of claim 3 wherein the antigen is a Borrelia antigen other than OspA.
- 6. The method of claim 5 wherein the antigen is OSPC.
- 7. The method of claim 1 wherein the lipoprotein is naturally lipidated.
- 8. The method of claim 1 wherein the lipoprotein is not naturally lipidated.
- 9. The method of claim 1 wherein the lipoprotein is an expression product of a hybrid nucleic acid molecule, comprising a first nucleic acid sequence encoding a signal sequence of a lipoprotein and a second nucleic acid sequence encoding a mature protein, or fragment thereof, which is heterologous to the lipoprotein encoded by the first nucleic acid sequence.
- 10. The method of claim 9 wherein, in the hybrid nucleic acid molecule, the signal sequence is the signal sequence of an OspA protein of a Borrelia species, and the sequences are contiguous.
- 11. The method of claim 10 wherein, in the hybrid nucleic acid molecule, the first nucleic acid sequence and the second nucleic acid sequence are coupled in a translational open reading frame relationship.
- 12. The method of claim 11 wherein, in the hybrid nucleic acid molecule, the mature protein is an OspC protein of a Borrelia species, or a fragment thereof.
- 13. The method of claim 12 wherein, in the hybrid nucleic acid molecule, the mature protein is an OspC protein from a strain of Borrelia burgdorferi.
- 14. The method of claim 13 wherein the strain of Borrelia burgdorferi is selected from the B31, ACA1 and Ip90 families of strains.
- 15. The method of claim 11 wherein, in the hybrid nucleic acid molecule, the mature protein is PspA or a fragment thereof.
- 16. The method of claim 15 wherein the antigen is an influenza antigen.
- 17. The method of claim 16 wherein the antigen is an HA antigen.
- 18. The method of claim 1 wherein the lipoprotein is antigenic.
- 19. The method of claim 18 wherein the lipoprotein is OspA.
- 20. The method of claim 1 wherein the antigen and lipoprotein are administered mucosally.
- 21. The method of claim 20 wherein the antigen and lipoprotein are administered intranasally.
- 22. The method of claim 20 wherein the antigen and lipoprotein are administered intragastrically.
- 23. The method of claim 20 wherein the antigen and lipoprotein are administered both intranasally and intragastrically.
- 24. The method of claim 1 wherein the immunological response is therapeutic.
- 25. The method of claim 1 wherein the immunological response is prophylactic.
- 26. A vaccine or immunogenic composition comprising:
an effective amount of at least one antigen; and an effective amount of at least one lipoprotein.
- 27. The composition of claim 26 wherein the antigen exhibits epitopes of a bacterial protein.
- 28. The composition of claim 27 wherein the antigen is urease.
- 29. The composition of claim 28 wherein the antigen is a Borrelia antigen other than OspA.
- 30. The composition of claim 29 wherein the antigen is OspC.
- 31. The composition of claim 26 wherein the lipoprotein is naturally lipidated.
- 32. The composition of claim 26 wherein the lipoprotein is, not. naturally lipidated.
- 33. The composition of claim 26 wherein the lipoprotein is an expression product of a hybrid nucleic acid molecule, comprising a first nucleic acid sequence encoding a signal sequence of a lipoprotein and a second nucleic acid sequence encoding a mature protein, or fragment thereof, which is heterologous to the lipoprotein encoded by the first nucleic acid sequence.
- 34. The composition of claim 33 wherein, in the hybrid nucleic acid molecule, the signal sequence is the signal sequence of an OspA protein of a Borrelia species, and the sequences are contiguous.
- 35. The composition of claim 34 wherein, in the hybrid nucleic acid molecule, the first nucleic acid sequence and the second nucleic acid sequence are coupled in a translational open reading frame relationship.
- 36. The composition of claim 35 wherein, an in the hybrid nucleic acid molecule the mature protein is an OspC protein of a Borrelia species, or a fragment thereof.
- 37. The composition of claim 37 wherein, the hybrid nucleic acid molecule, the mature protein is an OspC protein from a strain of Borrelia burgdorferi.
- 38. The composition of claim 37 wherein the strain of Borrelia burgdorferi is selected from the B31, ACA1 and Ip90 families of strains.
- 39. The composition of claim 35 wherein, in the hybrid nucleic acid molecule, the mature protein is PspA or a fragment thereof.
- 40. The composition of claim 39 wherein the antigen is an influenza antigen.
- 41. The composition of claim 40 wherein the antigen is an HA antigen.
- 42. The composition of claim 26 wherein the lipoprotein is antigenic.
- 43. The composition of claim 42 wherein the lipoprotein is an OspA protein of a Borrelia species.
REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of application Ser. No. 08/588,621, filed Jan. 19, 1996, which is a continuation-in-part of application Ser. No. 08/476,656, filed Jun. 7, 1995, now U.S. Pat. No. 6,251,405.
[0002] Reference, especially with respect to recombinant Borrelia proteins, is made to each of applications Ser. Nos. 07/973,338, filed Oct. 29, 1992; 08/373,455 (Rule 62 FWC of U.S. Ser. Nos. 07/973,338), filed Jan. 17, 1995, 07/888,765, filed May 27, 1992; 08/211,891, filed Oct. 16, 1992 (national phase of PCT/US92/08697); and 07/779,048, filed Oct. 18, 1991. Reference, especially with respect to structural genes of pneumococcal proteins, epitopic regions thereof, and administration of pneumococcal proteins, is made to each of applications Ser. Nos. 656,773, filed Feb. 15, 1991; 835,698, filed Feb. 12, 1992; 072,065, filed Jun. 3, 1993; 072,068, filed Jun. 3, 1993; 214,222 filed Mar. 17, 1994; 214,164, filed Mar. 17, 1994; 247,491, filed May 23, 1994; 048,896, filed Apr. 20, 1993; 246,636, filed May 20, 1994; 08/458,399 (continuation-in-part of application Ser. Nos. 246,636, filed October 7, 1994) filed Jun. 2, 1995; 08/446,201 filed May 19, 1995; 08/312,949, filed Sep. 30, 1994. With respect to Expression of Lipoproteins, reference is made to application Ser. No. 08/475,781, filed Jun. 7, 1995. And, with respect to Compostions and Methods for Administering Borrelia Burgdorferi Antigens mucosally, e.g., orally, for simulating an immunological response, reference is made to Barbour et al., application Ser. No. 08/588,637, filed Jan.19, 1996.
[0003] Each of the aforementioned applications is hereby incorporated herein by reference. Several documents are cited in the following text, and each is also hereby incorporated herein by reference.
Continuations (1)
|
Number |
Date |
Country |
Parent |
08588621 |
Jan 1996 |
US |
Child |
10096687 |
Mar 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08476656 |
Jun 1995 |
US |
Child |
08588621 |
Jan 1996 |
US |